$71.14
0.590.84%
At Close: -
$71.14
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Latest news for Biomarin Pharmaceutical (NASDAQ:BMRN) Stock
Biomarin Pharmaceutical Stock (NASDAQ: BMRN)
Categories: All
Wednesday, September 18, 2024
Tuesday, September 17, 2024
- Scotiabank Maintains Sector Perform on Biomar...
- Truist Securities Maintains Buy on Biomarin P...
- Wells Fargo Maintains Overweight on Biomarin ...
- RBC Capital Maintains Sector Perform on Bioma...
- GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
- B of A Securities Maintains Buy on Biomarin P...
- Stifel Maintains Buy on Biomarin Pharmaceutic...
- Bernstein Maintains Outperform on Biomarin Ph...
Monday, September 16, 2024
Friday, September 13, 2024
Tuesday, September 10, 2024
Monday, September 09, 2024
Friday, September 06, 2024
Thursday, September 05, 2024
- BioMarin Pharmaceuticals shares are trading l...
- JP Morgan Maintains Overweight on Biomarin Ph...
- RBC Capital Reiterates Sector Perform on Biom...
- Scotiabank Maintains Sector Perform on Biomar...
- BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
- Piper Sandler Maintains Overweight on Biomari...
- Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
- Truist Securities Maintains Buy on Biomarin P...
Wednesday, September 04, 2024
- Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
- BioMarin Pharmaceutical Shares Resume Trade
- Trading Halt: Halt status updated at 1:25:00 ...
- From BioMarin Investor Day, Co Provides New C...
- BioMarin Pharmaceutical Says Co Will Be Entit...
- BioMarin Pharmaceutical Says On Aug 28, Enter...
- Trading Halt: Halted at 10:30:00 a.m. ET - Tr...
Wednesday, August 28, 2024
Tuesday, August 27, 2024
Wednesday, August 21, 2024
Tuesday, August 20, 2024
Wednesday, August 07, 2024
Tuesday, August 06, 2024
- Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
- TD Cowen Maintains Buy on Biomarin Pharmaceut...
- Scotiabank Maintains Sector Perform on Biomar...
- Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
- BioMarin Pharmaceutical shares are trading hi...
- RBC Capital Reiterates Sector Perform on Biom...
- Barclays Maintains Overweight on Biomarin Pha...
- Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
- Evercore ISI Group Maintains Outperform on Bi...
- Stifel Maintains Buy on Biomarin Pharmaceutic...